Summit Plunges to ~$12 as FDA Rejects Ivonescimab Over Survival Data
Summit Therapeutics shares dropped after the FDA's complete response letter on ivonescimab. What it means for HARMONi-3, Akeso and rival PD-1xVEGF drugs.
Summit Therapeutics shares plunged on Monday, closing at $11.82, after the FDA declined to approve its lung-cancer drug ivonescimab. The stock fell about 16.5% from the prior close of $14.15 and hit a 52-week low, so investors are now weighing how long the delay could last and what it does to a richly valued biotech.
What happened
Summit announced on Sunday, Nov. 15 that the FDA had issued a complete response letter. The decision date had been Nov. 14. The agency said ivonescimab plus platinum chemotherapy cannot be approved in its current form for EGFR-mutated non-small cell lung cancer after prior EGFR TKI treatment. It said substantial evidence of effectiveness had not been established, and that a progression-free survival (PFS) benefit without a statistically significant overall survival (OS) improvement did not support approval. The pivotal HARMONi trial met its PFS goal, but the OS result was a positive trend that was not statistically significant. Summit points to a longer-term post-hoc OS hazard ratio of 0.76, which is not the primary analysis.
Partner Akeso fell as much as 32% in Hong Kong on Monday and closed down about 22% at HK$64.10.
Why it matters
The verdict is about evidence of survival, not safety: Summit described the safety profile as acceptable and manageable. The FDA is signaling that, in this setting, a PFS gain alone is not enough. BMO said overall survival remains the gold-standard bar in NSCLC.
That message reaches the whole PD-1xVEGF class. Pfizer's PF-08634404 and Merck's MK-2010 are earlier in clinical testing, so they have time to design trials around OS.
On cash, AstraZeneca's $2.0 billion equity investment was finalized in October, after the third quarter ended. That cushions a delay, but a new trial would add years of spending to a company that has no product revenue. Summit has also relied on at-the-market offerings and private placements in the past, which is one way a company funds itself and dilutes holders (see dilution).
Valuation was the debate before the CRL. Summit's value rested on approval and a first-line lung-cancer franchise, and this decision pushes revenue further out. Analyst views will likely be reassessed after the decision.
What to watch next
- HARMONi-3 (squamous cohort): A readout is due by year-end 2026. BMO calls it the most important near-term test of whether efficacy seen in China translates globally.
- Regulatory path: Whether Summit meets the FDA and what trial design it proposes.
- Funding and Akeso: Any new capital raise, and whether Akeso's slide stabilizes.
Small-cap biotech moves like this show why volatility and drawdowns matter for single-stock positions.
Stocks in this analysis
AI stock analysis- P/E
- 143.1
- Fwd P/E
- 15.9
- Analyst target (avg)
- $161.53 (+13%)
- P/E
- 25.8
- Fwd P/E
- 16.1
- Analyst target (avg)
- $208.07 (+14%)
Free on aktienanalyse.ai: score profile, ratios versus the industry and business model. Plus, if you want it, the full analysis with fair value and bull, base and bear case. Prices and ratios as of Nov 17, 2026.
Sources (6)
- Summit Stock Falls on FDA Rejection for Lung Cancer Drug
- Summit Therapeutics Provides Update Regarding Ivonescimab BLA
- FDA's Summit rejection puts PD-1xVEGF class on notice to establish overall survival – BioSpace
- Akeso shares plummet as Chinese firm's cancer drug ivonescimab faces FDA setback – SCMP
- Summit Therapeutics Q3 2026 results
- Summit Therapeutics Receives FDA Complete Response Letter for Ivonescimab – TipRanks
This analysis is for information only and is not investment advice. Prices and figures as of publication.